The long-term management of generalized anxiety disorder: Issues and dilemmas

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 7, 1996, Pages 9-13

  Schweizer, Edward ^a   Rickels, Karl ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY NEUROSIS; CHRONIC DISEASE; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; BUSPIRONE; CLINICAL TRIALS; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0029738591     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines: part I. N Engl J Med 1983;309:354-358
2. Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines: part II. N Engl J Med 1983;309:410-416
3. Rickels K, Wiseman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982;43:81-86
4. Schweizer E, Rickels K. Buspirone and related 5-HT compounds as anxiolytics. In: Nutt DJ, Mendelson WB, eds. Hypnotics and Anxiolytics. London, England: Bailliere Tindall; 1995:447-466
5. Kahn RJ, McNair DM, Lipman RS, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders, II: efficacy in anxious outpatients. Arch Gen Psychiatry 1986;43:79-85
6. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301
7. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993;50: 884-895
8. Rickels K, Case WG, Diamond L. Relapse after short-term drug therapy in neurotic outpatients. International Pharmacopsychiatry 1980;15:186-192
9. Rickels K, Case WG, Downing RW, et al. One-year follow-up of anxious patients treated with diazepam. J Clin Psychopharmacol 1986;6:32-36
10. Robins LN, Regier DA. Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York, NY: The Free Press; London, England: Collier Macmillan Publishers; 1991
11. Lewinsohn PM, Hops H, Roberts RE, et al. Adolescent psychopathology, I: prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol 1993;102:133-144
12. Whitaker A, Johnson J, Shaffer D, et al. Uncommon troubles in young people: prevalence estimates of selected psychiatric disorders in a non-referred adolescent population. Arch Gen Psychiatry 1990;47:487-496
13. Scheibe G, Albus M, Age at onset, precipitating events, sex distribution, and co-occurrence of anxiety disorders. Psychopathology 1992;25:11-18
14. Durham RC, Turvey AA. Cognitive therapy vs behavior therapy in the treatment of chronic general anxiety. Behav Res Ther 1987;25:229-234
15. Power KG, Simpson RJ, Swanson V, et al. A controlled comparison of cognitive-behavior therapy, diazepam, and placebo, alone and in combination, for the treatment of generalized anxiety disorder. Journal of Anxiety Disorders 1990;4:267-292
16. Butler G, Fennel M, Robson P, et al. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1991;59:167-175
17. Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1993;61:611-619
18. Chambless DL, Gillis MM. Cognitive therapy of anxiety disorders. J Consult Clin Psychol 1993;61:248-260
19. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993;150:600-607
20. Noyes R Jr, Woodman C, Garvey MJ, et al. Generalized anxiety disorder vs panic disorder: distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis 1992;180(6):369-379
21. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355-364
22. Sanderson WC, Wetzler S, Beck AT, et al. Prevalence of personality disorders among patients with anxiety disorders. Psychiatry Res 1994;51:167-174
23. Brown TA, Barlow DH. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 1992;60:835-844
24. Rickels K, Amsterdam J, Clary C, et al. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991;52:34-38
25. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10(suppl 3):67S-76S
26. Feighner JP, Aden GC, Fabre LF, et al. Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA 1983;249: 3057-3064
27. Rickels K, Chung HR, Csanalosi IB, et al. Alprazolam, diazepam, imipramine and placebo in outpatients with major depression. Arch Gen Psychiatry 1987;44:862-866
28. Sheehan DV, Raj AB, Sheehan KH, et al. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990;10:3-11
29. Pohl R, Balon R, Yeragani VK, et al. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989;22(suppl 1):60-67
30. Liebowitz MR, Gorman JM, Fyer AJ, et al. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988;49:252-257
31. Joffe RT, Bagby RM, Levitt A. Anxious and nonanxious depression. Am J Psychiatry 1993;150:1257-1258
32. Rickels K, Case WG, Downing RW, et al. Long-term diazepam therapy and clinical outcome. JAMA 1983;250:767-771
33. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal: prospective comparison of alprazolam and buspirone. Arch Gen Psychiatry 1988;45:444-450
34. Nagy LM, Krystal JH, Woods SW, et al. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. Arch Gen Psychiatry 1989;46:993-999
35. Rickels K, Schweizer E, Case WG, et al. Long-term therapeutic use of benzodiazepines, I: effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899-907. Correction 1991;48:51
36. Schweizer E, Rickels K, Case WG, et al. Long-term therapeutic use of benzodiazepines, II: effects of gradual taper. Arch Gen Psychiatry 1990;47: 908-915
37. Schweizer E, Rickels K, Case WG, et al. Carbamazepine treatment of benzodiazepine withdrawal. Arch Gen Psychiatry 1991;48:448-452
38. Rickels K, Schweizer E. Maintenance treatment studies in anxiety disorders: some methodological notes. Psychopharmacol Bull 1995;31: 115-123
39. NIH Consensus Conference. Drugs and insomnia. JAMA 1984;251: 2410-2414
40. Balter MB, Uhlenhuth EH. Prescribing and use of benzodiazepines: an epidemiologic perspective. J Psychoactive Drugs 1992;24:63-64
41. Lader M, Olajide D. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 1987;7: 11-15
42. Schweizer E, Rickels K. Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 1986;143:1590-1592
43. Ashton CH, Rawlins MD, Tyrer SP. A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry 1990;157:232-238
44. Delle Chiaie R, Pancheri P, Casacchia M, et al. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 1995;15:12-19
45. Otto MW, Pollack MH, Sachs GS, et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993;150:1485-1490